DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Basilea Pharmaceutica
Basilea Pharmaceutica
Basilea Successfully Placed 1 Million New Registered Shares, Raising Gross Proceeds of CHF 45.75 Million
PRESS RELEASE Basilea Announces Completion of the License Agreement Extension with Pfizer for Antifungal Cresemba® for China and Asia Pacific
Beyond Borders Global Biotechnology Report 2009 “It Is Different This Time Because This Crisis Is Deep-Rooted, Systemic and Persistent
Basilea Pharmaceutica Ltd. (BSLN.S) Initiation Report
Basilea Awarded CARB-X Grant of up to USD 2.7 Million to Develop Novel-Class Antibiotic
Information for Shareholders and Bondholders of Basilea Pharmaceutica AG
PRESS RELEASE Basilea Reports Significant Revenue Growth from Marketed Products and Pipeline Progress for Full-Year 2019
Basilea Pharmaceutica Interim Results
Astellas Entered Into Global Partnership with Basilea for an Azole Antifungal Agent Isavuconazole
Isavuconazole ISN 9766-CL-0104 Invasive Fungal Disease CONFIDENTIAL Eudract Number 2006-003868-59 Name of Sponsor/Company: Basil
METHODOLOGY Solactive Pharma Breakthrough Value Index
Synthetic Biology and the Computerization of Drug Development
Basilea Announces Completion of Its Transaction Involving a Partial Repurchase of Its Existing Bond and the Issuance of a New Bond
PRESS RELEASE Basilea's Toctino® (Alitretinoin) Receives First National Marketing Authorization in the UK
Basilea Announces Appointment of New Head of Global Quality Management
Background Context to Eurocentric Deals
Basilea Announces Divestment of Its Chinese R&D Subsidiary to PHT
Press Release Basilea Announces Closing of Previously Announced Transaction Regarding Divestment of Its Chinese R&D Subsidiary
Top View
Investor Presentation November 2019
Swiss Biotech Report 2018
Forest Runs Into Tree by Steve Usdin Biocentury This Week Washington Editor the Presentation Forest Laborato- Ries Inc
PRESS RELEASE Continued Strong Cresemba® (Isavuconazole) U.S
Basilea Pharmaceutica Focus on Oncology Assets
The Cost of Treating Mucormycosis with Isavuconazole Compared with Liposomal Amphotericin B Followed by Posaconazole in the Unit
Entered Into Global Partnership with Basilea for an Azole Antifungal Agent Isavuconazole Isavuconazole on a Worldwide Basis
Annual Report 2018 2 Annual Report 2018 Editorial
Swiss Biotech Report 2011